Steven J Katz1, Timothy P Hofer2, Christopher R Friese3, Jordan M Harrison3, Nancy K Janz4, Reshma Jagsi5, Monica Morrow6, Yun Li7, Ann S Hamilton8, Kevin C Ward9, Allison W Kurian10. 1. Departments of Internal Medicine and Health Management and Policy, Schools of Medicine and Public Health, University of Michigan. 2. Veterans Affairs Center for Clinical Management Research, Health Services Research and Development Service Center of Innovation and Department of Internal Medicine, University of Michigan. 3. Department of Systems, Populations, and Leadership, School of Nursing, and Institute for Healthcare Policy and Innovation, University of Michigan. 4. Department of Health Behavior and Health Education, School of Public Health, University of Michigan. 5. Department of Radiation Oncology, University of Michigan School of Medicine. 6. Memorial Sloan-Kettering Cancer Center. 7. Department of Biostatistics, University of Michigan School of Public Health. 8. University of Southern California Keck School of Medicine. 9. Rollins School of Public Health, Emory University. 10. Departments of Medicine and Health Research and Policy, Stanford University Medical Center.
Abstract
BACKGROUND: Patient-reported toxicities help to appraise the breast cancer treatment experience. Yet extant data come from clinical trials and health care claims, which may be biased. Using patient surveys, the authors sought to quantify the frequency, severity, and burden of treatment-associated toxicities. METHODS: Between 2013 and 2014, the iCanCare study surveyed a population-based sample of women residing in Los Angeles County and Georgia with early-stage, invasive breast cancer. The authors assessed the frequency and severity of toxicities; correlated toxicity severity with unscheduled health care use (clinic visits, emergency department visits/hospitalizations) and physical health; and examined patient, tumor, and treatment factors associated with reporting increased toxicity severity. RESULTS: The overall survey response rate was 71%. From the analyzed cohort of 1945 women, 866 (45%) reported at least 1 toxicity that was severe/very severe, 9% reported unscheduled clinic visits for toxicity management, and 5% visited an emergency department or hospital. Factors associated with reporting higher toxicity severity included receipt of chemotherapy (odds ratio [OR], 2.2; 95% confidence interval [95% CI], 2.0-2.5), receipt of both chemotherapy and radiotherapy (OR, 1.3; 95% CI, 1.0-1.7), and Latina ethnicity (OR vs whites: 1.3; 95% CI, 1.1-1.5). A nonsignificant increase in at least 1 severe/very severe toxicity report was observed for bilateral mastectomy recipients (OR, 1.2; 95% CI, 1.0-1.4). CONCLUSIONS: Women with early-stage invasive breast cancer report substantial treatment-associated toxicities and related burden. Clinicians should collect toxicity data routinely and offer early intervention. Toxicity differences observed by treatment modality may inform decision making. Cancer 2017;123:1925-1934.
BACKGROUND: Patient-reported toxicities help to appraise the breast cancer treatment experience. Yet extant data come from clinical trials and health care claims, which may be biased. Using patient surveys, the authors sought to quantify the frequency, severity, and burden of treatment-associated toxicities. METHODS: Between 2013 and 2014, the iCanCare study surveyed a population-based sample of women residing in Los Angeles County and Georgia with early-stage, invasive breast cancer. The authors assessed the frequency and severity of toxicities; correlated toxicity severity with unscheduled health care use (clinic visits, emergency department visits/hospitalizations) and physical health; and examined patient, tumor, and treatment factors associated with reporting increased toxicity severity. RESULTS: The overall survey response rate was 71%. From the analyzed cohort of 1945 women, 866 (45%) reported at least 1 toxicity that was severe/very severe, 9% reported unscheduled clinic visits for toxicity management, and 5% visited an emergency department or hospital. Factors associated with reporting higher toxicity severity included receipt of chemotherapy (odds ratio [OR], 2.2; 95% confidence interval [95% CI], 2.0-2.5), receipt of both chemotherapy and radiotherapy (OR, 1.3; 95% CI, 1.0-1.7), and Latina ethnicity (OR vs whites: 1.3; 95% CI, 1.1-1.5). A nonsignificant increase in at least 1 severe/very severe toxicity report was observed for bilateral mastectomy recipients (OR, 1.2; 95% CI, 1.0-1.4). CONCLUSIONS: Women with early-stage invasive breast cancer report substantial treatment-associated toxicities and related burden. Clinicians should collect toxicity data routinely and offer early intervention. Toxicity differences observed by treatment modality may inform decision making. Cancer 2017;123:1925-1934.
Authors: Jordan M Harrison; Philip J Stella; Beth LaVasseur; Paul T Adams; Lauren Swafford; JoAnn Lewis; Kari Mendelsohn-Victor; Christopher R Friese Journal: J Oncol Pract Date: 2016-07-12 Impact factor: 3.840
Authors: B J Paessens; C von Schilling; K Berger; M Shlaen; C Müller-Thomas; R Bernard; C Peschel; A Ihbe-Heffinger Journal: Ann Oncol Date: 2011-02-22 Impact factor: 32.976
Authors: Gary H Lyman; David C Dale; Jonathan Friedberg; Jeffrey Crawford; Richard I Fisher Journal: J Clin Oncol Date: 2004-09-20 Impact factor: 44.544
Authors: Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: Carolyn D Runowicz; Corinne R Leach; N Lynn Henry; Karen S Henry; Heather T Mackey; Rebecca L Cowens-Alvarado; Rachel S Cannady; Mandi L Pratt-Chapman; Stephen B Edge; Linda A Jacobs; Arti Hurria; Lawrence B Marks; Samuel J LaMonte; Ellen Warner; Gary H Lyman; Patricia A Ganz Journal: CA Cancer J Clin Date: 2015-12-07 Impact factor: 508.702
Authors: Ann S Hamilton; Timothy P Hofer; Sarah T Hawley; Donna Morrell; Meryl Leventhal; Dennis Deapen; Barbara Salem; Steven J Katz Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-06-23 Impact factor: 4.254
Authors: Allison W Kurian; Irina Bondarenko; Reshma Jagsi; Christopher R Friese; M Chandler McLeod; Sarah T Hawley; Ann S Hamilton; Kevin C Ward; Timothy P Hofer; Steven J Katz Journal: J Natl Cancer Inst Date: 2018-05-01 Impact factor: 13.506
Authors: Nicholas L Berlin; Paul Abrahamse; Adeyiza O Momoh; Steven J Katz; Reshma Jagsi; Ann S Hamilton; Kevin C Ward; Sarah T Hawley Journal: Cancer Date: 2021-11-30 Impact factor: 6.860
Authors: Cheryl Duzenli; Elisa K Chan; Alanah M Bergman; Sheri Grahame; Joel Singer; Levi Burns; Robert A Olson Journal: BMC Cancer Date: 2022-06-20 Impact factor: 4.638
Authors: Christopher R Friese; Alex J Fauer; Clare Kuisell; Kari Mendelsohn-Victor; Nathan C Wright; Jennifer J Griggs; Milisa Manojlovich Journal: Health Serv Res Date: 2020-10-30 Impact factor: 3.402